Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 29 tags : Fda save search
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
RFL 4 | $1.71 -4.09% 0
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda potential test therapy cancer gastrointestinal drug cpi-613 milestone designation
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
Published: 2021-06-29 (Crawled : 16:00) - globenewswire.com
RFL 4 | $1.71 -4.09% 0
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda cancer drug cpi-613 granted grant designation
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
Published: 2021-06-29 (Crawled : 14:15) - biospace.com/
CGEM | $18.89 5.5K
|
|
| O: -0.42%
H: 4.09%
C: -0.15%
new drug fda clearance treatment fda solid tumors antibody drug clearance
Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib)
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 4.03%
H: 0.0%
C: -5.27%
fda biopharma fda approval approval lonafarnib rare
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License ApplicationCompany Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
VCEL | $46.11 1.2K
|
Health Technology
|
| O: -15.34%
H: 4.46%
C: 0.63%
MDWD | $17.59 7.19% 6.44% 210
|
Health Technology
|
| O: -33.51%
H: 14.13%
C: 8.53%
fda potential therapy license approval
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
ABMD | $381.02 0.06% 0.07%
|
Health Technology
|
| O: -0.36%
H: 1.48%
C: 0.63%
fda heart approval granted grant
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.5%
H: 0.89%
C: -3.47%
CNSP | News | $0.205 -4.21% 18K
|
Health Technology
|
| O: 33.33%
H: 0.0%
C: -20.52%
berubicin treatment fda fast track fast track designation granted grant designation glioblastoma
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
Published: 2021-06-29 (Crawled : 13:00) - globenewswire.com
VCEL | $46.11 1.2K
|
Health Technology
|
| O: -15.34%
H: 4.46%
C: 0.63%
MDWD | $17.59 7.19% 6.44% 210
|
Health Technology
|
| O: -33.51%
H: 14.13%
C: 8.53%
fda license application response
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
Published: 2021-06-29 (Crawled : 12:00) - prnewswire.com
PTN | $1.73 -1.14% 0.58% 0
|
Health Technology
|
| O: 7.22%
H: 15.17%
C: 15.17%
dry eye disease treatment fda phase 2 eye positive eye disease
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.